Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05928195 · ClinicalTrials.gov registry record · NA
Acute Effects of Organic Guayusa Extract
A NA study, sponsored by Nathaniel Jenkins.
- Completed
- Registry status
- NA
- Development phase
- 32
- Enrollment target
NCT05928195: Completed NA study, sponsored by Nathaniel Jenkins.
NCT05928195 is a NA study that has completed, run by Nathaniel Jenkins. The registered enrollment target is 32 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05928195, a NA study, has completed, sponsored by Nathaniel Jenkins.
- COMPLETED
- Registry status
- NA
- Development phase
- 32 participants
- Enrollment target
Study Summary
Guayusa extract is a caffeinated tea leaf unique blend of antioxidants and caffeine. It is marketed as an ingredient that can help support energy and performance with potential health-related benefits. It has also been indicated as being as safe as any other existing teas (i.e., green tea). However, no studies have previous studied the dose-response effects of guayusa extract for supporting cognitive function, mood, metabolism, nor its effects on resting heart rate, blood pressure, and electrocardiogram characteristics.
Primary Outcome
Calculated as Total Mood Disturbance (arbitrary units) using the Profile of Mood States Short Form Questionnaire.
Interventions
- DIETARY_SUPPLEMENT Placebo
- DIETARY_SUPPLEMENT Acute Moderate-Dose Guayusa Extract Supplementation
- DIETARY_SUPPLEMENT Acute High-Dose Guayusa Extract Supplementation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 2022-05-16 |
| Est. Completion | 2023-04-12 |
| Phase | NA |
What the finished NCT05928195 record still lists
NCT05928195 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 32 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (98% lower).
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT05928195 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05928195 about?
NCT05928195 is a clinical study titled "Acute Effects of Organic Guayusa Extract". Guayusa extract is a caffeinated tea leaf unique blend of antioxidants and caffeine. It is marketed as an ingredient that can help support energy and performance with potential health-related benefits. It has also been indicated as being as safe as any other existing teas (i.e., green tea). However,...
What is the current status of trial NCT05928195?
This trial is currently completed. It is a NA study. The enrollment target is 32 participants. The study started on 2022-05-16. Estimated completion is 2023-04-12.
What interventions are being tested in trial NCT05928195?
The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Acute Moderate-Dose Guayusa Extract Supplementation (DIETARY_SUPPLEMENT), Acute High-Dose Guayusa Extract Supplementation (DIETARY_SUPPLEMENT).
Who is sponsoring clinical trial NCT05928195?
This trial is sponsored by Nathaniel Jenkins, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05928195's enrollment target sits among peer trials
32 1578th of 2000 higher than 409 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02445781 · 32 participants · Early Phase 1
Differing Levels of Hypoglycemia
- NCT02792270 · 32 participants · NA
Caloric Restriction In Sarcoma Patients Treated With Pre-Operative RT
- NCT03068910 · 32 participants · Early Phase 1
Hyperandrogenemia and Altered Day-night LH Pulse Patterns
- NCT03208868 · 32 participants · NA
Leucine Enriched Essential Amino Acid Mixture to Reverse Muscle Loss in Cirrhosis
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI